Medtronic PLC $MDT Shares Sold by Bahl & Gaynor Inc.

Bahl & Gaynor trimmed its stake in Medtronic by 1.2% in Q2 to 48,009 shares ($4.19m) according to a 13F filing, while several other managers materially added positions—notably Avantax (+12.7% to 146,432 shares) and Brighton Jones (up 1,368% to ~39,989 shares)—leaving institutional ownership at roughly 82.1%. Shares opened at $101.16 (up ~1.8%), trading near a 52-week high with a $129.8bn market cap, P/E of 27.9 and PEG of 2.42, as analysts have pushed price targets higher (consensus “Moderate Buy,” avg. PT $109.72; Citi, Morgan Stanley, Leerink among those raising targets). Insider activity was mixed—EVP Harry Skip Kiil sold 8,605 shares while director William Jellison bought 2,500—underscoring continued institutional interest and analyst optimism that support the stock’s sentiment, although investors should monitor execution against elevated valuation.

Analysis

Bahl & Gaynor trimmed its Medtronic position by 1.2% in Q2, selling 580 shares to finish with 48,009 shares valued at $4.185 million, while several other institutions materially added exposure—Avantax increased to 146,432 shares (+12.7%, $13.158m) and Brighton Jones expanded to ~39,989 shares after a 1,368% increase—leaving institutional ownership at ~82.06%. Insider activity was mixed: EVP Harry Skip Kiil sold 8,605 shares at $91.58 (a 19.46% reduction to 35,615 shares) while director William Jellison purchased 2,500 shares at $92.37, doubling his stake to 5,000 shares. Shares opened at $101.16 (up 1.8%), trading close to a 52-week high of $102.59 with a $129.76 billion market cap, P/E of 27.87, PEG of 2.42, and 50-/200-day moving averages of $95.04/$90.94. Multiple brokerages have raised targets (Citi $112, Morgan Stanley $117, Leerink $120) producing a MarketBeat consensus of Moderate Buy and an average target of $109.72, which underpins analyst-driven upside but requires operational execution to be realized.

Institutional accumulation alongside analyst upgrades supports near-term positive sentiment and potential upside toward consensus targets, yet valuation metrics imply expectations are elevated and susceptible to guidance or execution misses. The high concentration of institutional ownership can amplify flows and volatility around quarterly earnings, 13F disclosures and further insider transactions. Monitor upcoming quarterly results and any shift in insider selling or large fund reallocations for confirmation of the current constructive thesis, as momentum alone may not sustain a re-rating without demonstrated revenue/earnings delivery.

Key Decisions for Investors

• Consider adding modestly on weakness toward the 50‑day moving average (~$95) rather than at current levels to improve entry given analyst upgrades and an average price target of $109.72,
• Maintain disciplined position sizing or hedge new exposure because the P/E of 27.87 and PEG of 2.42 reflect elevated expectations that require confirmed execution,
• Monitor the next quarterly results, guidance and subsequent 13F/insider filings closely and be prepared to trim or hedge if insider selling accelerates or guidance disappoints,
• Follow institutional flow trends—continued net additions by large advisors (e.g., Avantax, Brighton Jones) would support the bull case, so increase exposure only after multi‑quarter follow‑through